Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Authors:
- Anette Arbjerg HøjenAHAnette Arbjerg Højen
- Peter Brønnum NielsenPNPeter Brønnum Nielsen
- Thure Filskov OvervadTOThure Filskov Overvad
- Ida Ehlers AlbertsenIAIda Ehlers Albertsen
- Frederikus A. KlokFKFrederikus A. Klok
- Nanna RolvingNRNanna Rolving
- Mette SøgaardMSMette Søgaard
- Anne Gulbech OrdingAOAnne Gulbech Ording
Open Access
- 10 October 2022
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5970
Abstract
The concept of pulmonary embolism is evolving. Recent and emerging evidence on the treatment of specific patient populations, its secondary prevention, long-term complications, and the unmet need for rehabilitation has the potential to change clinical practice for the benefit of the patients. This review discusses the recent evidence from clinical trials, observational studies, and guidelines focusing on anticoagulation treatment, rehabilitation, emotional stress, quality of life, and the associated outcomes for patients with pulmonary embolism. Guidelines suggest that the type and duration of treatment with anticoagulation should be based on prevalent risk factors. Recent studies demonstrate that an anticoagulant treatment that is longer than two years may be effective and safe for some patients. The evidence for extended treatment in cancer patients is limited. Careful consideration is particularly necessary for pulmonary embolisms in pregnancy, cancer, and at the end of life. The rehabilitation and prevention of unnecessary deconditioning, emotional distress, and a reduced quality of life is an important, but currently they are unmet priorities for many patients with a pulmonary embolism. Future research could demonstrate optimal anticoagulant therapy durations, follow-ups, and rehabilitation, and effective patient-centered decision making at the end of life. A patient preferences and shared decision making should be incorporated in their routine care when weighing the benefits and risks with primary treatment and secondary prevention.Keywords
This publication has 94 references indexed in Scilit:
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancerJournal of Thrombosis and Haemostasis, 2012
- Low-Dose Aspirin for Preventing Recurrent Venous ThromboembolismNew England Journal of Medicine, 2012
- Aspirin for Preventing the Recurrence of Venous ThromboembolismNew England Journal of Medicine, 2012
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Quality of Life in Long-term Survivors of Acute Pulmonary EmbolismChest, 2010
- Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolismRespiratory Medicine, 2010
- Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic eventThrombosis and Haemostasis, 2009
- Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With CancerArchives of internal medicine (1960), 2002